Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study - Concepedia

Concepedia

Publication | Open Access

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

DOI Full Paper Access

117

Citations

25

References

2018

Year

Pamela N. Münster, Ian E. Krop, Patricia LoRusso, Barry A. Siegel, Anthony F. Shields, István Molnár, Thomas J. Wickham, Joseph G. Reynolds, Karen Campbell, Bart S. Hendriks,

British Journal of Cancer

References

	Year	Citations

Page 1